Actavis to spend $66B on Botox-maker Allergan

SHARE Actavis to spend $66B on Botox-maker Allergan
SHARE Actavis to spend $66B on Botox-maker Allergan

Actavis is paying $66 billion to buy fellow drugmaker Allergan in a deal that could finally end a months-long takeover battle waged by Valeant Pharmaceuticals for the Botox maker.

Actavis said Monday that it will spend $219 in cash and stock for each share of Allergan.

That tops a bid for Allergan valued at about $53 billion and made last spring by Valeant Pharmaceuticals International Inc. and the hedge fund Pershing Square Capital Management. That offer totaled about $179 in cash and stock.

Allergan resisted the Valeant deal for months, but its board has unanimously approved the Actavis offer.

The Latest
Chicago officials expect the city will be declared a high risk for COVID-19 outbreaks and strain on hospitals.
Other California cities, like Santa Cruz and Pacific Grove, banned polystyrene foam cups and containers, and polystyrene litter decreased by as much as 71%.
Left-hander Tanner Banks was recalled from Triple-A Charlotte to take Kelly’s place in the bullpen.
Una legislación propuesta aún no ha sido aprobada por el Senado, donde seguramente no se aprobará debido a la oposición del Partido Republicano.
La mamá había ido a dejar a sus hijos mayores a la escuela y regresaba a casa con el desayuno cuando se enteró del incendio, dijo.